ATOSSA THERAPEUTICS, INC.
Business
Atossa Therapeutics is a clinical-stage biopharmaceutical company developing proprietary oral (Z)-endoxifen, a selective estrogen receptor modulator and degrader (SERM/D), currently in Phase 2 clinical development for breast cancer and other breast conditions. The company is evaluating (Z)-endoxifen across multiple breast cancer settings including neoadjuvant, adjuvant, and breast density reduction indications, as well as exploring applications in gynecological cancers, Duchenne muscular dystrophy, and McCune-Albright Syndrome. Atossa conducts clinical trials through third-party contractors and contract research organizations and has established a proprietary manufacturing process for (Z)-endoxifen with defined processes and qualified suppliers.
Summary from 10-K filed 2026-03-25
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Research and development | 21 | 14 | 17 | 15 | 9 | |
| General and administrative | 16 | 14 | 14 | 13 | 11 | |
| Total operating expenses | 37 | 28 | 31 | 28 | 21 | |
| Operating loss | −37 | −28 | −31 | −28 | −21 | |
| Impairment charge on investment in equity securities | 0 | −2 | −3 | 0 | — | |
| Interest income | 2 | 4 | 4 | 877,000 | 6,000 | |
| Other expense, net | −6,000 | −223,000 | −70,000 | −146,000 | −91,000 | |
| Loss before income taxes | −35 | −26 | −30 | −27 | −21 | |
| Income taxes benefit | 0 | 0 | 0 | 0 | 0 | |
| Net loss | −35 | −26 | −30 | −27 | −21 | |
| Net loss per share of common stock - basic (in dollars per share) | −4.04 | −3.04 | −0.24 | −0.21 | −0.18 | |
| Net loss per share of common stock - diluted (in dollars per share) | −4.04 | −3.04 | −0.24 | −0.21 | — | |
| Weighted average shares outstanding used to compute net loss per share- basic (in shares) | 9 | 8 | 126 | 127 | 117 | |
| Weighted average shares outstanding used to compute net loss per share - diluted (in shares) | 9 | 8 | 126 | 127 | — |
Consolidated Balance Sheet
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 41 | 71 | 88 | 111 | 136 | |
| Restricted cash | 110,000 | 110,000 | 110,000 | 110,000 | 110,000 | |
| Prepaid materials | 3 | 2 | 1 | 5 | — | |
| Prepaid expenses and other current assets | 1 | 1 | 2 | 1 | — | |
| Total current assets | 46 | 74 | 92 | 118 | 141 | |
| Other assets | 2 | 2 | 2 | 635,000 | 22,000 | |
| Total Assets | 48 | 76 | 96 | 124 | 141 | |
| Accounts payable | 4 | 679,000 | 806,000 | 3 | 2 | |
| Accrued expenses | 1 | 919,000 | 973,000 | 1 | 204,000 | |
| Payroll liabilities | 2 | 2 | 2 | 2 | 1 | |
| Other current liabilities | 1 | 2 | 2 | 19,000 | 21,000 | |
| Total current liabilities | 8 | 5 | 5 | 6 | 3 | |
| Total Liabilities | 8 | 5 | 5 | 6 | 3 | |
| Commitments and contingencies (Note 13) | — | — | — | — | — | |
| Common stock - $0.18 par value; 350,000,000 shares authorized 8,611,361 and 8,611,266 shares issued and outstanding as of December 31, 2025 and 2024 | 2 | 2 | 23 | 23 | 23 | |
| Additional paid-in capital | 286 | 283 | 256 | 251 | — | |
| Treasury stock, at cost; 88,003 shares of common stock at December 31, 2025 and 2024 respectively | −1 | −1 | −1 | 0 | — | |
| Accumulated deficit | −247 | −212 | −186 | −156 | −129 | |
| Total Stockholders' Equity | 39 | 71 | 91 | 118 | 138 | |
| Total Liabilities and Stockholders' Equity | 48 | 76 | 96 | 124 | 141 |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Stock-based compensation | 3 | 2 | 5 | 7 | — | |
| Depreciation | 16,000 | 17,000 | 23,000 | 8,000 | — | |
| Loss on disposal of assets | 0 | 7,000 | 0 | 3,000 | 0 | |
| Prepaid materials | −983,000 | −611,000 | 3 | −3 | −674,000 | |
| Prepaid expenses and other current assets | 37,000 | 997,000 | 1 | 180,000 | — | |
| Other assets | 4,000 | 331,000 | −2 | −597,000 | 0 | |
| Accounts payable | 4 | −127,000 | −2 | 1 | 128,000 | |
| Accrued expenses | 388,000 | −54,000 | −86,000 | 855,000 | 111,000 | |
| Payroll liabilities | −304,000 | 208,000 | 129,000 | 341,000 | 220,000 | |
| Other current liabilities | −410,000 | −296,000 | 2 | −2,000 | 17,000 | |
| Net cash used in operating activities | −30 | −21 | −21 | −21 | −16 | |
| Purchase of property and equipment | −23,000 | −19,000 | −14,000 | −27,000 | −9,000 | |
| Net cash used in investing activities | −23,000 | −19,000 | −14,000 | −5 | −9,000 | |
| Proceeds from exercise of warrants | 0 | 4 | 0 | 0 | 44 | |
| Net cash provided by financing activities | 0 | 4 | −1 | 0 | 113 | |
| NET DECREASE IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH | −30 | −17 | −22 | −25 | 97 | |
| Common stock issued upon cashless exercise of stock options | 0 | 273,000 | 0 | 0 | 1 | |
| Conversion of Series B convertible preferred stock to common stock | 5,000 | 0 | — | — | — |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is ATOSSA THERAPEUTICS, INC.'s CIK number?
ATOSSA THERAPEUTICS, INC.'s SEC CIK number is 0001488039 (1488039). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find ATOSSA THERAPEUTICS, INC.'s SEC filings?
All of ATOSSA THERAPEUTICS, INC.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.
When did ATOSSA THERAPEUTICS, INC. last report earnings?
ATOSSA THERAPEUTICS, INC. (ATOS) most recently filed an earnings 8-K with the SEC on Jan 9, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001193125-26-008314). This is ATOSSA THERAPEUTICS, INC.'s most recent earnings filing of record — not a forecast of its next earnings date.
What is ATOSSA THERAPEUTICS, INC.'s most recent earnings 8-K?
ATOSSA THERAPEUTICS, INC.'s latest earnings 8-K (Item 2.02) was filed Jan 9, 2026 under accession 0001193125-26-008314. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.
View ATOSSA THERAPEUTICS, INC.'s latest earnings 8-K →
Look up any company's CIK number →